ScholarIQanswers from OpenAlex
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
PaperCitations, authors & open-access status
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial have?
ScholarIQcitation count
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial has 794 citations in the OpenAlex counts ScholarIQ stores.
When was Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial published?
ScholarIQyear
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial has 2020 year in the ScholarIQ index.
What is the open-access status of Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial?
ScholarIQoa status
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial has green oa status in the ScholarIQ index.
What is the DOI of Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial?
ScholarIQdoi
The DOI for Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial is on the source record.
What is the OpenAlex record for Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial?
ScholarIQopenalex
The OpenAlex for Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial is on the source record.